MCC-950
| Overview | |
| Catalog # | bs-82624c-5mg |
| Product Name | MCC-950 |
| Specifications | |
| Storage Buffer | White solid |
| Storage Condition | -20°C |
| Target | |
| Product Information | MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-11. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes2. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)3. Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome4. A valuable new tool for exploring the pathophysiology of NLRP3. |
| Description | CAS Number: 210826-40-7 Chemical Name: N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt Molecular weight: 426.46 Formula: C20H23N2O5S Na Solubility: DMSO (40 mg/ml) Water (30 mg/ml) Physical Properties: White solid Purity: 98% by HPLC NMR (Conforms) |